THROMBOSIS MORNING REPORT - ANXIETY PROVOKING THROMBOSIS CONSULTS (TC-101)

Saturday, October 28, 2023

08:30 – 09:20 EST

Location: Palais, 519AB

Chair(s)

Marc Carrier, MD, FRCPC, MSc

Physician
Ottawa Hospital
University of Ottawa

Panelist(s)

Kerstin de Wit, MBChB, MSC, MD, MRCP, FRCEM, FRCPC (she/her/hers)

Associate Professor
Queen's University
Queen's University
Grégoire Le Gal (he/him/his)

Co-Director
CanVECTOR
University of Ottawa
Deborah Siegal, MD, MSc, FRCPC

Hematologist; Associate Professor, Dept. of Medicine; Associate Scientist, Clinical Epidemiology
Ottawa Hospital Research Institute
Ottawa Hospital Research Institute
Eric Tseng, MD, MScHS, FRCPC

Disclosure(s):

Marc Carrier, MD, FRCPC, MSc: Bayer: Speaker/Honoraria (Ongoing); BMS: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Leo Pharma: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Servier: Speaker/Honoraria (Ongoing)

Kerstin de Wit, MBChB, MSC, MD, MRCP, FRCEM, FRCPC: No financial relationships to disclose

Grégoire Le Gal: BMS: Speaker/Honoraria (Terminated); Fresenius-Kabi: Consultant/Advisory Board (Terminated); Inari: Consultant/Advisory Board (Terminated); Leo Pharma: Speaker/Honoraria (Terminated); Pfizer: Speaker/Honoraria (Terminated); Sanofi: Consultant/Advisory Board (Ongoing)

Deborah Siegal, MD, MSc, FRCPC: Astra Zeneca: Speaker/Honoraria (Terminated, November 17, 2022); BMS-Pfizer: Speaker/Honoraria (Ongoing); Roche: Speaker/Honoraria (Ongoing); Servier: Speaker/Honoraria (Ongoing)

Eric Tseng, MD, MScHS, FRCPC: Fresenius Kabi: Consultant/Advisory Board (Ongoing); Inari Medical: Consultant/Advisory Board (Ongoing); Pfizer pharmaceuticals: Consultant/Advisory Board (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

identify risk factors associated with higher-risk of anticoagulation-associated bleeding;
summarize the evidence for the management of patients with recurrent VTE despite anticoagulation; and
balance risks and benefits of anticoagulant therapy in patients with VTE at high risk of bleeding.

Start your day like a thrombosis fellow. Thrombosis expert Marc Carrier will challenge the audience and our "fellows" with complicated patient presentations.